Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Risk factors for tooth loss in community-dwelling Japanese aged 40 years and older: the Yamagata (Takahata) study.

Ishikawa S, Konta T, Susa S, Kitabatake K, Ishizawa K, Togashi H, Tsuya A, Ueno Y, Kubota I, Yamashita H, Kayama T, Iino M.

Clin Oral Investig. 2019 Apr;23(4):1753-1760. doi: 10.1007/s00784-018-2604-x. Epub 2018 Aug 30.

PMID:
30167794
2.

Scientific Misconduct and Social Media: Role of Twitter in the Stimulus Triggered Acquisition of Pluripotency Cells Scandal.

Sugawara Y, Tanimoto T, Miyagawa S, Murakami M, Tsuya A, Tanaka A, Kami M, Narimatsu H.

J Med Internet Res. 2017 Feb 28;19(2):e57. doi: 10.2196/jmir.6706.

3.

Medical Institutions and Twitter: A Novel Tool for Public Communication in Japan.

Sugawara Y, Narimatsu H, Tsuya A, Tanaka A, Fukao A.

JMIR Public Health Surveill. 2016 May 12;2(1):e19. doi: 10.2196/publichealth.4831. eCollection 2016 Jan-Jun.

4.

The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients.

Miura S, Kaira K, Kaira R, Akamatsu H, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Murakami H, Takahashi T, Endo M, Yamamoto N.

Invest New Drugs. 2015 Jun;33(3):755-60. doi: 10.1007/s10637-015-0233-7. Epub 2015 Apr 7.

PMID:
25846908
5.

Disease flare after gefitinib discontinuation.

Akamatsu H, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Murakami H, Endo M, Nakajima T, Yamamoto N, Takahashi T.

Respir Investig. 2015 Mar;53(2):68-72. doi: 10.1016/j.resinv.2014.10.005. Epub 2014 Nov 13.

PMID:
25745851
6.

A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.

Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y, Katsushima U, Tsuya A, Tokunaga S, Daga H, Okuno T, Inoue T.

Jpn J Clin Oncol. 2014 Sep;44(9):868-71. doi: 10.1093/jjco/hyu069. Epub 2014 Jul 15.

PMID:
25028698
7.

Do cancer patients tweet? Examining the twitter use of cancer patients in Japan.

Tsuya A, Sugawara Y, Tanaka A, Narimatsu H.

J Med Internet Res. 2014 May 27;16(5):e137. doi: 10.2196/jmir.3298.

8.

[Evaluation of recurrence rates on change in hormone receptor and human epidermal growth factor receptor 2 status after neo-adjuvant chemotherapy in breast cancer patients].

Tokunaga S, Ikeda K, Ogawa Y, Fukushima H, Inoue T, Shibata Y, Kimbara S, Katsushima U, Okada H, Tsuya A, Taira K, Daga H, Takeda K.

Gan To Kagaku Ryoho. 2014 Mar;41(3):313-6. Japanese.

PMID:
24743275
9.

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.

Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, Boku N, Nishio K, Fukuoka M, Yamamoto N, Nakagawa K.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1063-71. doi: 10.1007/s00280-013-2277-8. Epub 2013 Sep 18.

PMID:
24046058
10.

A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.

Tsuya A, Kurata T, Tamiya A, Okamoto I, Ueda S, Sakai D, Sugimoto N, Matsumoto K, Goto I, Yamamoto N, Fukuoka M, Nakagawa K.

Invest New Drugs. 2013 Dec;31(6):1568-72. doi: 10.1007/s10637-013-0014-0. Epub 2013 Aug 24.

PMID:
23975509
11.

Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.

Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Yoshikawa T, Naito T, Takahashi T, Murakami H, Nakamura Y, Tsuya A, Shukuya T, Ono A, Akamatsu H, Watanabe R, Ono S, Mori K, Kanbara H, Yamaguchi K, Tanaka T, Matsunaga T, Yamamoto N.

PLoS One. 2013 Jun 28;8(6):e67466. doi: 10.1371/journal.pone.0067466. Print 2013.

12.

A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer.

Kurahashi I, Fujita Y, Arao T, Kurata T, Koh Y, Sakai K, Matsumoto K, Tanioka M, Takeda K, Takiguchi Y, Yamamoto N, Tsuya A, Matsubara N, Mukai H, Minami H, Chayahara N, Yamanaka Y, Miwa K, Takahashi S, Takahashi S, Nakagawa K, Nishio K.

PLoS One. 2013 May 9;8(5):e63249. doi: 10.1371/journal.pone.0063249. Print 2013.

13.

Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.

Wakuda K, Kenmotsu H, Naito T, Akamatsu H, Ono A, Shukuya T, Nakamura Y, Tsuya A, Murakami H, Takahashi T, Endo M, Nakajima T, Yamamoto N.

Am J Clin Oncol. 2015 Feb;38(1):28-32. doi: 10.1097/COC.0b013e318286907b.

PMID:
23388567
14.

Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens.

Tokito T, Kenmotsu H, Watanabe R, Ito I, Shukuya T, Ono A, Nakamura Y, Tsuya A, Naito T, Murakami H, Takahashi T, Ohde Y, Kondo H, Endo M, Kameya T, Nakajima T, Mori K, Yamamoto N.

Int J Clin Oncol. 2014 Feb;19(1):63-7. doi: 10.1007/s10147-012-0509-2. Epub 2012 Dec 19.

PMID:
23250620
15.

The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.

Akamatsu H, Kaira K, Murakami H, Serizawa M, Koh Y, Ono A, Shukuya T, Tsuya A, Nakamura Y, Kenmotsu H, Naito T, Takahashi T, Endo M, Harada H, Nakajima T, Yamamoto N.

Am J Clin Oncol. 2014 Apr;37(2):144-7. doi: 10.1097/COC.0b013e31826e04f9.

PMID:
23211219
16.

Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan.

Kenmotsu H, Ohde Y, Shukuya T, Eida H, Akamatsu H, Ono A, Nakamura Y, Tsuya A, Kaira K, Naito T, Murakami H, Takahashi T, Maniwa T, Isaka M, Endo M, Kondo H, Yamamoto N.

Respir Investig. 2012 Dec;50(4):157-61. doi: 10.1016/j.resinv.2012.09.002. Epub 2012 Oct 27.

PMID:
23199980
17.

Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors.

Miura S, Murakami H, Tamiya A, Morii S, Akamatsu H, Ono A, Syukuya T, Kenmotsu H, Tsuya A, Nakamura Y, Kaira K, Naito T, Takahashi T, Endo M, Nakajima T, Yamamoto N.

Oncol Lett. 2011 Nov;2(6):1059-1064. Epub 2011 Aug 31.

18.

A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

Hasegawa Y, Okamoto I, Takezawa K, Miyazaki M, Tsurutani J, Yonesaka K, Morinaga R, Tsuya A, Terashima M, Kudoh T, Azuma K, Kurata T, Nishikawa T, Fukuoka M, Nishimura Y, Nakagawa K.

Invest New Drugs. 2013 Jun;31(3):599-604. doi: 10.1007/s10637-012-9833-7. Epub 2012 May 24.

PMID:
22623066
19.

Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis.

Nakamura Y, Takahashi T, Tsuya A, Naito T, Kenmotsu H, Ono A, Shukuya T, Murakami H, Harada H, Watanabe R, Endo M, Mitsuya K, Nakajima T, Yamamoto N.

Anticancer Res. 2012 May;32(5):1811-6.

PMID:
22593466
20.

Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer.

Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Yamamoto N, Endo M.

Anticancer Res. 2012 Mar;32(3):1103-6.

PMID:
22399640
21.

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy.

Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Ono A, Naito T, Tsuya A, Nakamura Y, Endo M, Kondo H, Nakajima T, Yamamoto N.

Int J Clin Oncol. 2013 Jun;18(3):371-9. doi: 10.1007/s10147-012-0386-8. Epub 2012 Feb 23.

PMID:
22358390
22.

¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?

Kaira K, Endo M, Shukuya T, Kenmotsu H, Naito T, Ono A, Tsuya A, Nakamua Y, Takahashi T, Murakami H, Kondo H, Nakajima T, Yamamoto N.

Neoplasma. 2012;59(3):257-63. doi: 10.4149/neo_2012_033.

PMID:
22329847
23.

Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer.

Ono A, Naito T, Ito I, Watanabe R, Shukuya T, Kenmotsu H, Tsuya A, Nakamura Y, Murakami H, Kaira K, Takahashi T, Kameya T, Nakajima T, Endo M, Yamamoto N.

Lung Cancer. 2012 Jun;76(3):439-44. doi: 10.1016/j.lungcan.2011.12.012. Epub 2012 Jan 31.

PMID:
22300752
24.

Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.

Shukuya T, Takahashi T, Harada H, Akamatsu H, Sakaguchi C, Imai H, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, Yamamoto N.

Anticancer Res. 2012 Feb;32(2):675-80.

PMID:
22287762
25.

Prognostic impact of circulating tumor cells in patients with small cell lung cancer.

Naito T, Tanaka F, Ono A, Yoneda K, Takahashi T, Murakami H, Nakamura Y, Tsuya A, Kenmotsu H, Shukuya T, Kaira K, Koh Y, Endo M, Hasegawa S, Yamamoto N.

J Thorac Oncol. 2012 Mar;7(3):512-9. doi: 10.1097/JTO.0b013e31823f125d.

26.

Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.

Takahashi T, Boku N, Murakami H, Naito T, Tsuya A, Nakamura Y, Ono A, Machida N, Yamazaki K, Watanabe J, Ruiz-Garcia A, Imai K, Ohki E, Yamamoto N.

Invest New Drugs. 2012 Dec;30(6):2352-63. doi: 10.1007/s10637-011-9789-z. Epub 2012 Jan 17.

27.

Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.

Inomata M, Shukuya T, Takahashi T, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Murakami H, Harada H, Endo M, Yamamoto N.

Anticancer Res. 2011 Dec;31(12):4519-23.

PMID:
22199325
28.

Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors.

Kaira K, Ohde Y, Endo M, Nakagawa K, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Kondo H, Nakajima T, Yamamoto N.

Oncol Rep. 2011 Oct;26(4):931-7. doi: 10.3892/or.2011.1384. Epub 2011 Jul 11.

PMID:
21750865
29.

The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.

Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, Tsuya A, Kaira K, Murakami H, Takahashi T, Endo M, Yamamoto N.

J Thorac Oncol. 2011 Jul;6(7):1242-6. doi: 10.1097/JTO.0b013e318216ee6b.

30.

Phase I results of vinorelbine with concurrent radiotherapy in elderly patients with unresectable, locally advanced non-small-cell lung cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI).

Harada H, Seto T, Igawa S, Tsuya A, Wada M, Kaira K, Naito T, Hayakawa K, Nishimura T, Masuda N, Yamamoto N.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1777-82. doi: 10.1016/j.ijrobp.2011.03.037. Epub 2011 May 27.

PMID:
21621337
31.

Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.

Shukuya T, Takahashi T, Naito T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Murakami H, Harada H, Mitsuya K, Endo M, Nakasu Y, Takahashi K, Yamamoto N.

Lung Cancer. 2011 Dec;74(3):457-61. doi: 10.1016/j.lungcan.2011.04.007. Epub 2011 May 14.

PMID:
21571388
32.

Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors.

Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Murakami H, Tsuya A, Nakamura Y, Naito T, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N.

Lung Cancer. 2011 Dec;74(3):419-25. doi: 10.1016/j.lungcan.2011.04.001. Epub 2011 May 7.

PMID:
21550686
33.

Thenar muscle metastasis as recurrence of pulmonary squamous cell carcinoma.

Kaira K, Ayabe E, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Takahashi M, Yamamoto N.

Asia Pac J Clin Oncol. 2011 Mar;7(1):15-6. doi: 10.1111/j.1743-7563.2010.01373.x. Epub 2011 Jan 24. No abstract available.

PMID:
21332646
34.

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.

Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N.

Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28.

35.

18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors.

Kaira K, Murakami H, Miura S, Kaira R, Akamatsu H, Kimura M, Ono A, Tsuya A, Nakamura Y, Naito T, Takahashi T, Endo M, Yamamoto N.

Ann Nucl Med. 2011 May;25(4):247-53. doi: 10.1007/s12149-010-0455-x. Epub 2010 Dec 21.

PMID:
21174178
36.

Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.

Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N.

Cancer Chemother Pharmacol. 2011 Sep;68(3):653-9. doi: 10.1007/s00280-010-1519-2. Epub 2010 Dec 2.

37.

Intestinal metastasis from non-small-cell lung cancer initially detected by ¹⁸F-fluorodeoxyglucose positron emission tomography.

Akamatsu H, Tsuya A, Kaira K, Nakamura Y, Naito T, Murakami H, Takahashi T, Endo M, Yamamoto N.

Jpn J Radiol. 2010 Nov;28(9):684-7. doi: 10.1007/s11604-010-0470-9. Epub 2010 Nov 27.

PMID:
21113753
38.

Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.

Kaira K, Endo M, Asakura K, Tsuya A, Nakamura Y, Naito T, Murakami H, Takahashi T, Yamamoto N.

Ann Nucl Med. 2010 Dec;24(10):697-705. doi: 10.1007/s12149-010-0412-8. Epub 2010 Sep 8.

PMID:
20824397
39.

CD98 expression is associated with the grade of malignancy in thymic epithelial tumors.

Kaira K, Takahashi T, Abe M, Akamatsu H, Nakagawa K, Ohde Y, Okumura T, Murakami H, Tsuya A, Nakamura Y, Naito T, Kondo H, Nakajima T, Endo M, Yamamoto N.

Oncol Rep. 2010 Oct;24(4):861-7.

PMID:
20811665
40.

Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.

Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K.

Mol Cancer Ther. 2010 Oct;9(10):2825-33. doi: 10.1158/1535-7163.MCT-10-0379. Epub 2010 Aug 5.

41.

Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.

Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Kondo H, Nakajima T, Yamamoto N.

Lung Cancer. 2011 Feb;71(2):144-50. doi: 10.1016/j.lungcan.2010.05.021. Epub 2010 Jun 19.

PMID:
20646779
42.

Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors.

Kaira K, Endo M, Abe M, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Hayashi I, Serizawa M, Koh Y, Hanaoka H, Tominaga H, Oriuchi N, Kondo H, Nakajima T, Yamamoto N.

J Clin Oncol. 2010 Aug 10;28(23):3746-53. doi: 10.1200/JCO.2009.27.4662. Epub 2010 Jul 12.

PMID:
20625125
43.

Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more.

Tamiya A, Naito T, Ono A, Ayabe E, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Endo M, Yamamoto N.

Lung Cancer. 2011 Feb;71(2):173-7. doi: 10.1016/j.lungcan.2010.05.014. Epub 2010 Jun 8.

PMID:
20570388
44.

[Evaluation of chemotherapy, especially combined therapy with Carboplatin Plus Etoposide(CE), in patients aged > or =80 years old with extensive-disease small-cell lung cancer].

Tamiya A, Tsuya A, Nakamura Y, Kaira K, Naitou T, Murakami H, Takahashi T, Endo M, Yamamoto N.

Gan To Kagaku Ryoho. 2010 Jun;37(6):1041-4. Japanese.

PMID:
20567104
45.

N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases.

Kaira R, Murakami H, Kaira K, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N.

Int J Clin Oncol. 2010 Oct;15(5):484-8. doi: 10.1007/s10147-010-0100-7. Epub 2010 Jun 17.

PMID:
20556457
46.

Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer.

Ono A, Naito T, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Kaira K, Igawa S, Shukuya T, Tamiya A, Kaira R, Endo M, Yamamoto N.

Int J Clin Oncol. 2010 Apr;15(2):161-5. doi: 10.1007/s10147-010-0034-0. Epub 2010 Mar 4. Erratum in: Int J Clin Oncol. 2010 Jun;15(3):331. Shukuya, Takehiro [corrected to Shukuya, Takehito].

PMID:
20198400
47.

Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.

Kaira K, Horie Y, Ayabe E, Murakami H, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Kondo H, Nakajima T, Yamamoto N.

J Thorac Oncol. 2010 Apr;5(4):460-5. doi: 10.1097/JTO.0b013e3181ce3e3c.

48.

Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6.

Ayabe E, Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N.

Int J Clin Oncol. 2009 Dec;14(6):534-6. doi: 10.1007/s10147-009-0875-6. Epub 2009 Dec 5. Erratum in: Int J Clin Oncol. 2010 Feb;15(1):116.

PMID:
19967491
49.

Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer.

Harada H, Yamamoto N, Takahashi T, Endo M, Murakami H, Tsuya A, Nakamura Y, Ono A, Igawa S, Shukuya T, Tamiya A, Nishimura T.

Int J Clin Oncol. 2009 Dec;14(6):507-12. doi: 10.1007/s10147-009-0907-2. Epub 2009 Dec 5.

PMID:
19967486
50.

Features of gemcitabine-related severe pulmonary toxicity: patients with pancreatic or biliary tract cancer.

Tamiya A, Endo M, Shukuya T, Igawa S, Tsuya A, Nakamura Y, Murakami H, Takahashi T, Boku N, Yamamoto N.

Pancreas. 2009 Oct;38(7):838-40. doi: 10.1097/MPA.0b013e3181ad97cf. No abstract available.

PMID:
19893461

Supplemental Content

Support Center